CD274 and lung adenocarcinoma: All of the patients with squamous NSCLC (n = 7), 1 with lung adenocarcinoma, and 7 with SCCHN were relapsed or refractory to anti–PD-1/PD-L1 checkpoint inhibitor therapy.